title: [Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer].
abstract: OBJECTIVE
  To investigate the clinical effect of intraoperative peritoneal hyperthermic chemotherapy (IPHC) for advanced gastric cancer (AGC).
  
  
  METHODS
  A total of 118 AGC patients with serosal invasion were enrolled in this study from 1998 to 2001. Among these cases, 96 patients without macroscopic peritoneal metastases were selected for prophylactic study, including 42 cases with IPHC and 54 cases without IPHC as control. Other 22 patients with macroscopic peritoneal metastases were selected for therapeutic study, including 10 cases with IPHC and 12 without IPHC. Postoperative survival rate and peritoneal recurrence were compared.
  
  
  RESULTS
  For prophylactic study, the 1, 2 and 4 years survival rates were 85.7%, 81.0% and 63.9% respectively in the patients with IPHC,significantly higher than 77.3%, 61.0% and 50.8% in the patients without IPHC. Cox ratio hazard model revealed that IPHC procedure was an independent prognostic factor. More patients in the control group suffered from peritoneal recurrence than those in IPHC group (34.7% vs 10.3%). For therapeutic study,the median survival period of the patients with IPHC was 10 months, higher than 5 months in the patients without IPHC. The overall 1, 2, 4 year survival rates were 76.9%, 69.2%, 55.2% respectively in all cases with IPHC, higher than 66.2%, 49.7%, 41.4% in the cases without IPHC.
  
  
  CONCLUSIONS
  IPHC procedure can improve the prognosis of AGC patients with serosal invasion, reduce the risk for peritoneal recurrence, and is an independent prognostic factor.
authors.affiliation: Department of General Surgery, Ruijin Hospital, Shcool of Medicine, Shanghai Jiaotong University, Shanghai Institute of Digestive Surgery, Shanghai 200025, China. digsurg@online.sh.cn
authors.forename: Zheng-gang
authors.initials: ZG
authors.lastname: Zhu
authors.forename: Rui
authors.initials: R
authors.lastname: Tang
authors.forename: Min
authors.initials: M
authors.lastname: Yan
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.forename: Qiu-meng
authors.initials: QM
authors.lastname: Yang
authors.forename: Shen
authors.initials: S
authors.lastname: Li
authors.forename: Xue-xin
authors.initials: XX
authors.lastname: Yao
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: Hao-ran
authors.initials: HR
authors.lastname: Yin
authors.forename: Yan-zhen
authors.initials: YZ
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate; D016896:Treatment Outcome